Inhibition of BCL-2 by antisense oligonucleotides is followed by a compensatory suppression of caspase-3 in LNCaP cells

European journal of Clinical and Medical Oncology

Volumn 3, Issue 2, 2011, Pages 1-6

  Rubenstein, Marvin ^a,b,c,d   Hollowell, Courtney M P ^d   Guinan, Patrick ^a,c,d,e  

^a Hektoen Institute for Medical Research   (United States)

^b Department of Biochemistry ^*  (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d Jr Hospital of Cook County   (United States)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antisense oligonucleotides; Bax; Bcl 2; Caspase 3; Prostate cancer; Therapy

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; LIPOFECTIN; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2;

ANTISENSE THERAPY; APOPTOSIS; ARTICLE; BINDING SITE; CANCER CELL; CELL GROWTH; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; GENE AMPLIFICATION; GENE IDENTIFICATION; GENETIC VARIABILITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PROMOTER REGION; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN TARGETING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 79958189220     PISSN: 17598958     EISSN: 17598966     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Rubenstein M, Tsui P, Guinan P. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors. Med Hypotheses. 2005;65:905-907.
2. Rubenstein M, Tsui P, Guinan P. Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy. Methods Find Exp Clin Pharmacol. 2006;28:515-518.
3. Rubenstein M, Tsui P, Guinan P. Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and BCL-2 for the treatment of prostate cancer. Med Oncol. 2007;24:372-378.
4. Rubenstein M, Tsui P, Guinan P. Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors. Comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel. Med Oncol. 2009;26: 124-130.
5. Rubenstein M, Tsui P, Guinan P. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and BCL-2 for the treatment of prostate tumors. Med Oncol. 2007;24:189-196.
6. Yamanaka K, Miyake H, Zangemeister-wittke U, Jansen B, Gleave M. Novel bispecific antisense oligonucleotides inhibiting both BCL-2 and Bcl-xL expression induce apoptosis and enhance chemosensitivity in human androgen-independent prostate cancer cells. Proc Am Assoc Cancer Res. 2004;45:Abstract #2930 (online).
7. Takahara K, Muramaki M, Li D, Cox ME, Gleave ME. Insulin-like growth factor-binding protein-5 (IGFBP5) supports prostate cancer cell proliferation. J Urol. 2009;181:184a.
8. Rubenstein M, Mirochnik Y, Bremer E, George D, Freilich L, Guinan P. Inhibitory effect of antisense oligonucleotides targeting epidermal growth factor receptor may not be related to changes in mRNA levels in human prostate carcinoma cells. Proc Am Assoc Cancer Res. 2002;43:590a.
9. Rubenstein M, Tsui P, Guinan P. A review of antisense oligonucleotides in the treatment of human disease. Drugs Future. 2004;29:893-909.
10. Rubenstein M, Tsui P, Guinan P. Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2. Med Oncol. 2008;25:182-186.
11. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, Tindall DJ. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of BCL-2 expression. J Biol Chem. 2001;276:38830-38836.
12. Salakou S, Kardamakis D, Tsamandas AC, et al. Increased bax.BCL-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of patients with myasthenia gravis. In Vivo. 2007;21:123-132.
13. Perlman H, Zhang X, Chen MW, Walsh K, Buttyan R. An elevated bax/ BCL-2 ratio corresponds with the onset of prostate epithelial cell apoptosis. Cell Death Differ. 1999;6:48-54.
14. Yip KW, Mocanu JD, Au PY, et al. Combination BCL-2 antisense and radiation therapy for nasopharyngeal cancer. Clin Cancer Res. 2005;11: 8131-8144.
15. Mu Z, Hachem P, Pollack A. Antisense BCL-2 sensitizes prostate cancer cells to radiation. Prostate. 2005;65:331-340.
16. Rubenstein M, Anderson KM, Tsui P, Guinan P. Synthesis of branched antisense oligonucleotides having multiple specificities. Treatment of hormone insensitive prostate cancer. Med Hypotheses. 2006;67:1375-1380.